The Amgen company has announced that a new analysis of the study of cardiovascular events called Fourier, has shown that the reduction of cholesterol levels linked to low density lipoproteins with repathha (Evolocumab) reduced significantly and consistently and consistent the cardiovascular events in patients,whether or not they present diabetes at the beginning of the study.
The analysis showed that diabetes was independently associated with a considerable increase in the risk of cardiovascular morbidity and mortality in patients with atherosclerotic disease.
Patients with diabetes presented a tendency to a greater reduction in the absolute risk of cardiovascular events with Evolocumab treatment, due to their highest basal risk.Consistently with recent more intense decrease in C-LDL, Evolocumab has not shown to have effect on cardiovascular mortality.
The analysis also evidenced that Evolocumab was not associated with an increase in the risk of new appearance diabetes, nor to a worsening of blood glucose during a median of 2.2 years of follow -up in patients with diabetes or prediabetes.
In addition, no new security findings were identified in this analysis, whose results have been presented in the framein The Lancet Diabetes & AMP;Endocrinology.
Marc Sabatine, president of the Timi Study Group, explained that “this analysis also demonstrates the benefits of reaching C-LDL levels well below the current objectives in patients with atherosclerotic cardiovascular disease with and without diabetes,The first of which have a significantly higher risk of cardiovascular events and therefore tend to experience a greater reduction in absolute risk. ”
"It should be noted that this analysis also provides new evidence that Evolocumab is equally insurance in patients with and without diabetes," said Dr. Sabatine, who is also director of the Department of Cardiovascular Medicine of the Brigham and Women's Hospital and principal author of theanalysis.
According to Sean Harper, Executive Vice President of Research and Development of AMGEN, “this analysis provides new evidence of a considerable increase in the risk of cardiovascular events in patients with diabetes and reaffirms the importance of repathha as an appropriate treatment option for these patients with greater risk, due to a greater reduction of absolute risk with treatment ”.